These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 25891971)
1. Diacylglycerol Kinase ζ (DGKζ) Is a Critical Regulator of Bone Homeostasis Via Modulation of c-Fos Levels in Osteoclasts. Zamani A; Decker C; Cremasco V; Hughes L; Novack DV; Faccio R J Bone Miner Res; 2015 Oct; 30(10):1852-63. PubMed ID: 25891971 [TBL] [Abstract][Full Text] [Related]
2. Phospholipase Cγ1 (PLCγ1) Controls Osteoclast Numbers via Colony-stimulating Factor 1 (CSF-1)-dependent Diacylglycerol/β-Catenin/CyclinD1 Pathway. Yang Z; Kim S; Mahajan S; Zamani A; Faccio R J Biol Chem; 2017 Jan; 292(4):1178-1186. PubMed ID: 27941021 [TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of phospholipase C γ2 adaptor function blocks osteoclastogenesis and protects from pathological osteolysis. Decker C; Hesker P; Zhang K; Faccio R J Biol Chem; 2013 Nov; 288(47):33634-33641. PubMed ID: 24081142 [TBL] [Abstract][Full Text] [Related]
4. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189 [TBL] [Abstract][Full Text] [Related]
5. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment. Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522 [TBL] [Abstract][Full Text] [Related]
6. Vitamin C-deficiency stimulates osteoclastogenesis with an increase in RANK expression. Hie M; Tsukamoto I J Nutr Biochem; 2011 Feb; 22(2):164-71. PubMed ID: 20444587 [TBL] [Abstract][Full Text] [Related]
7. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo. Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes. Hirata K; Taki H; Shinoda K; Hounoki H; Miyahara T; Tobe K; Ogawa H; Mori H; Sugiyama E Biol Pharm Bull; 2010; 33(1):133-7. PubMed ID: 20045951 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms involved in enhancement of osteoclast formation by activin-A. Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562 [TBL] [Abstract][Full Text] [Related]
10. DGKζ Downregulation Enhances Osteoclast Differentiation and Bone Resorption Activity Under Inflammatory Conditions. Iwazaki K; Tanaka T; Hozumi Y; Okada M; Tsuchiya R; Iseki K; Topham MK; Kawamae K; Takagi M; Goto K J Cell Physiol; 2017 Mar; 232(3):617-624. PubMed ID: 27312515 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB. Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671 [TBL] [Abstract][Full Text] [Related]
13. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833 [TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731 [TBL] [Abstract][Full Text] [Related]
15. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways. Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253 [TBL] [Abstract][Full Text] [Related]
16. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB. Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321 [TBL] [Abstract][Full Text] [Related]
17. SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion. Zhou Y; Mohan A; Moore DC; Lin L; Zhou FL; Cao J; Wu Q; Qin YX; Reginato AM; Ehrlich MG; Yang W FASEB J; 2015 May; 29(5):1635-45. PubMed ID: 25593124 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis. Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732 [TBL] [Abstract][Full Text] [Related]
19. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. Kim MH; Ryu SY; Choi JS; Min YK; Kim SH J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ). Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]